Recce Pharmaceuticals Ltd.ASX: RCE

License and Commercialisation Agreement in AUS/NZ for R327G

Oct 21, 2026 at 6:45 PM EDT · Issued by Recce Pharmaceuticals Ltd. via ASX

Filed with ASX · Oct 21, 2026 at 6:45 PM EDT

On 6ix: 6ix.com/news/license-and-commercialisation-agreement-in-ausnz-for-r327g-1

ASX Announcement Recce Pharmaceuticals and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization ® Agreement for RECCE 327 for Diabetic Foot Infections in Australia and New Zealand SYDNEY and MELBOURNE Australia, 22 October 2026: Recce Pharmaceuticals Ltd (ASX: RCE; FSE: R9Q)...

View Attachment

6ix is reading this filing.

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

Independent Review of Indonesian Phase 3 R327G Trial DataOct 19
Amendments to Debt Facility with Avenue Capital GroupOct 16
Appendix 4E and FY26 Annual ReportAug 31
HREC Approves Comparator Study for Pivotal Phase 3 DFIAug 18
Vietnamese Patent Granted for RECCE Anti-InfectivesJul 13

All Recce Pharmaceuticals news releases

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals